Les jugements rendus entre le 26 septembre 2018 et le 18 janvier 2019 par différents Conseils de Prud’hommes[1] et dont il a beaucoup été question ont d’abord rassuré, puis inquiété, et inquiètent encore, six parmi ceux traités ici ayant écarté l’application du barème Macron contre deux qui l’ont appliqué. Les contentieux à l’origine des jugements rendus dont il sera question ici sont de trois ordres : Licenciements ; Résiliations judiciaires aux torts de l’employeur ; Requalification d’un…
The U.S. Department of Health and Human Services (HHS) recently proposed two new rules designed to increase patient and provider access to health records. As stated by HHS in its press release, the proposed rules “will support seamless and secure access, exchange, and use of electronic health information.” These proposed rules stem from two separate components within HHS – the Centers for Medicare & Medicaid Services (CMS) and the Office of the National Coordinator for Health…
The Federal Court of Appeal (“FCA”) upheld the validity of Canadian Patent 2,436,668 (“668 Patent”) which covers Form I ODV succinate (marketed as PRISTIQ) in two separate appeals by Apotex Inc. (“Apotex”) and Teva Canada Ltd (“Teva”), finding that the claims were novel and inventive. Obviousness The FCA began be reiterating key points of the obviousness analysis: The Sanofi test is flexible and expansive and can include consideration of the invention story as a whole;…
GenomeDx Biosciences Corp., which markets a genomic test (Decipher®) intended to assess the aggressiveness of prostate cancer, has agreed to pay $1.99 million to the U.S. Department of Justice to resolve allegations that it violated the False Claims Act (31 U.S.C. §§ 3729 et seq.)(“FCA”) by submitting claims to Medicare for tests conducted to evaluate treatment options for men after prostate surgery. The government and a whistleblower alleged that between September 2015 and June 2017, GenomeDx…
On 14 February 2019, the Court of Justice of the EU (CJEU) delivered its judgment in Case C-423/17 Netherlands v Warner-Lambert Company, finding in line with the opinion of Advocate General Kokott issued on 4 October 2018, that “carving-out” indications or dosage forms covered by the patent right of a third party, leading to a skinny label for the product, is a request to limit the marketing authorisation for the generic medicinal product. In…
En réaction au mouvement des « gilets jaunes », le Président de la République a annoncé des mesures en faveur du pouvoir d’achat qui ont été adoptées par la loi portant mesures d’urgence économiques et sociales le 24 décembre 2018. Parmi ces mesures, deux retiennent particulièrement l’attention : la prime de 1.000€ exemptée de charges sociales et d’impôt sur le revenu des personnes physiques et la défiscalisation partielle des heures supplémentaires, avec exonération partielle de cotisations sociales. Prime…
When Title IX of the Education Amendments of 1972, 20 U.S.C. § 1681, et seq. (“Title IX”), which prohibits many forms of discrimination on the basis of sex, appears in the news or on social media, we typically associate it with traditional colleges and universities.  But recent case law suggests that Title IX likely applies to a broader set of institutions, including, under certain circumstances, some hospitals. Over the years, an extensive body of federal…
Take heart, Americans. Taking care of ourselves makes a difference, making us healthier — and saving us money.  New research supports policies for spending on the wellness of the elderly, improving heart care, and how smart interventions can reduce rising overall health costs. This evidence-based approach to figuring the government’s optimal role in individuals’ health also may provide a rebuke of sorts to the way that partisans are imposing draconian new rules to
Private equity (PE) investors entered the physician practice management (PPM) market in 2011, and eight years later the PPM sector continues to be a ripe middle market for PE investors looking to diversify their portfolios. However, as the healthcare market continues to change in light of increasing vertical integration between payors and providers and disruption caused by new players such as Amazon, changes may be on the horizon for PE investment in the PPM space.…
With equal parts hope and optimism, we look ahead to an eventful New Year. This is particularly true for the physician practice management (PPM) industry: we reflect on the progress of the past while looking forward to the opportunities today’s growing and increasingly complex landscape provides. We believe the trends we’ve seen shape the industry will continue to be influential, including: The growing involvement of private equity investors Last year, we hosted the 2018 Health